腹膜透析患者への水素溶解透析液経腹膜投与による腹腔内酸化ストレス抑制の検討
Peritoneal dialysis (PD) patients experience oxidative stress driven by glucose degradation products such as methylglyoxal, which contributes to peritoneal membrane deterioration. Conventional antioxidant agents carry safety concerns that limit their use. In this study, six PD patients underwent peritoneal equilibrium testing with both standard and hydrogen-enriched dialysate. Albumin redox status in effluent and serum was quantified by high-performance liquid chromatography. The fraction of reduced albumin in effluent was significantly elevated with hydrogen-enriched dialysate (62.31 ± 11.10%) compared with standard dialysate (54.70 ± 13.08%). Serum reduced albumin also increased from 62.44 ± 7.66% to 65.75 ± 7.52% following hydrogen-enriched dialysate administration. These findings indicate that transperitoneal H2 delivery attenuates oxidative stress both locally in the peritoneal cavity and systemically.
Hydrogen dissolved in dialysate selectively scavenges reactive oxygen species generated by glucose degradation products such as methylglyoxal within the peritoneal cavity, resulting in a measurable increase in the proportion of reduced albumin in both effluent and serum.
Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).
See also:
https://h2-papers.org/en/papers/23816239